Japanese Website

HomeMichael Jaramillo2024-01-09T21:17:33+00:00

The Future of
Drug Discovery is Here.

Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. We leverage our proprietary end-to-end platform to enable our biotechnology and pharmaceutical partners to deliver benefits to patients around the world.

whoweare-img2

Who We Are

Axcelead is your trusted drug discovery and development partner.

We were formed in 2017 as a Takeda spin-out with a singular vision in mind – to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines.

What We Do

Oncology, immunology, neuroscience drug discovery and so much more.

At Axcelead, we are focused on accelerating the discovery and development of high-value drug classes through our end-to-end platform, enabling our biotechnology and pharmaceutical partners to deliver benefit to patients around the world.

Targeted Protein Degraders

Targeted Protein Degradation

Axcelead has comprehensive capabilities in TPD drug discovery at the preclinical stages and a proven track record.

RNA-Targeted Small Molecules

RNA-Targeted
Small Molecules

Axcelead has comprehensive capabilities in integrated RNA-targeted small molecule drug discovery at the preclinical stages.

Target Identification

Target Identification / Validation

Target Identification would have a significant impact in drug discovery research. Axcelead offers the platform to support the identification of novel drug target using human data driven transcriptomics and proteomics. Target validation of identified candidates is also performed in Axcelead using human samples and a variety of animal disease models.

HIT Identification

Hit Identification / Characterization

Axcelead will design a robust HTS strategy, starting from assay development through hit characterization, based on 700+ HTS experiences. Using carefully curated library sets from 1.5 million compounds inherited from a pharmaceutical company, we have achieved a success hit identification rate of 90+%.

Lead Generation

Lead Generation / Optimization

Axcelead has all must-have functions for efficient lead generation and optimization in one place, covering medicinal and analytical chemistries as well as in vitro and in vivo biology including DMPK and safety evaluation. Furthermore, Axcelead also uses proprietary in-silico systems with AI and high throughput synthesis technology to guide rational drug design and compound delivery.

Candidate Selection

Candidate Selection

Candidate Selection is vital in drug discovery as in which, the optimized compounds are evaluated whether they are feasible for IND application filing and clinical studies. The candidate compound is selected and proposed based on the results of human effective dose prediction and safety assessment. Axcelead offers you one-stop and high-quality candidate selection by our accumulated experience.

IND Enabling

Our proprietary process is designed to accelerate the development project time of your drug from candidate selection to IND filing, reduce R&D costs and achieve an IND in under 12 months. Smart-IND is a one-stop shop with Axcelead

Advancing Oncology Research

We harness our wealth of expertise in target identification/validations, in vitro cell based assays, in vivo studies and translational research to achieve compounds with optimal profiles to perform well in the preclinical, clinical and real-world settings.

Advancing Immunology Research

Our proprietary process focusses on obtaining the right immune and inflammatory reactions in cells from multiple species in our preclinical models, obtaining efficacy in our preclinical models and creating a novel MOA at our facility utilizing human tissue and blood samples.

Advancing Cardiovascular / Metabolic Disease Research

Cardiovascular and metabolic diseases are complicated diseases involving various organs, and drug discovery requires deep expertise. At Axcelead, our team has abundant experience in drug discovery for heart failure, kidney diseases, obesity, MASH, etc.

Neuroscience Research

Advancing Neuroscience Research

When you partner with us, we will validate the scientific hypothesis of hitting a particular target based on the change of gene and protein expression using iPSC, patient-derived CSF, plasma and brain cells. Further, we will evaluate the potential of your compound using various measures of brain function and efficacy with behavioral tests specific to the development of neuroscience drugs.

IND Enabling Projects

IND-Enabling Projects

Axcelead acquired multiple projects from Takeda through its spin-out in 2017 in multiple therapeutic areas including Oncology, Inflammation and Immunology, Metabolic Disorders and neuroscience. These exciting projects are available for co-creation of drug candidates with our customers.

High Throughput Screening

High Throughput Screening

Our integrated High Throughput Screening (HTS) platform, including a pharma-origin library of 1.5 million compounds, assay development capabilities, and a track record of over 700 projects, helps you rapidly identify your hit compounds.

Chemistry

Axcelead leverages our expertise and technologies of rational drug design and synthetic chemistry to create the medicines of the future

Oligonucleotide

Oligonucleotide

Safety and delivery are the main challenges associated with discovering and developing complex oligonucleotides therapies. Axcelead offers a comprehensive platform that excels in repeating both in vivo and in vitro evaluations in the short term and proposing optimal solutions to help our partners overcome these challenges.

Peptide

A Comprehensive One-Stop Solution for All Your Peptide Drug Discovery Challenges!

Axcelead has intelligent platform technologies to create peptide therapeutics with optimized profiles suitable for clinical development.

Small Molecules

Small Molecules

Small molecule drugs have been the dominant form in pharmaceuticals to date, and even as modalities diversify in the future, they are expected to continue to comprise the majority of newly approved drugs.

Client Outcomes

We are your trusted partner.

At Axcelead, we have an aggressive mission to become the most trusted drug development solutions provider to leading biotechnology and pharmaceutical companies. Our wealth of expertise and knowledge stems from our robust client base, with over 100 facilities including pharmaceutical companies, venture companies and academia utilizing its services.

Our current partners in the US consist of cutting-edge companies developing new and proven drug candidates and modalities for oncology, immunology and neuroscience indications.

20

New Drug Applications

100

Successful IND Complete

90%

Hit Ratio of Screening

News

Our latest news and press releases.

Research results of a mouse model of chronic kidney disease (AXCC mice) generated in Axcelead DDP has been published in the American Journal of Pathology as a co-authored article.

A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked Alport...

10.31.2024|

A Co-authored Paper regarding Immunocompromised type 1 Diabetic Mini-pigs was Published in the Cell Transplantation

Xenogenic Engraftment of Human Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-pig...

10.21.2024|

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

September 10, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as...

09.10.2024|

We are ready to partner with you.